Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Biologics Files for $300 Million (?) Hong Kong IPO

publication date: Jan 25, 2017
WuXi Biologics, the biologics arm of CRO/CMO WuXi AppTec, has filed to conduct its much-anticipated IPO on the Hong Kong Exchange. Trouble is, all the information about the transaction itself is redacted: there is no target for money raised, number of shares offered or timetable. Even the word "IPO" is carefully edited out of the document, leaving REDACTED in its place. Knowledgeable observers expect the IPO to take place in Q2, raise $300 million and value WuXi Biologics at $1.5 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital